Loading...

Heike Wulff

TitleAssoc Prof
InstitutionUniversity of California Davis
Address
vCardDownload vCard

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Slavi N, Toychiev AH, Kosmidis S, Ackert J, Bloomfield SA, Wulff H, Viswanathan S, Lampe PD, Srinivas M. Suppression of connexin 43 phosphorylation promotes astrocyte survival and vascular regeneration in proliferative retinopathy. Proc Natl Acad Sci U S A. 2018 Jun 11. PMID: 29891713.
      View in: PubMed
    2. Grimaldi A, D'Alessandro G, Di Castro MA, Lauro C, Singh V, Pagani F, Sforna L, Grassi F, Di Angelantonio S, Catacuzzeno L, Wulff H, Limatola C, Catalano M. Kv1.3 activity perturbs the homeostatic properties of astrocytes in glioma. Sci Rep. 2018 May 16; 8(1):7654. PMID: 29769580.
      View in: PubMed
    3. Mishra RC, Rahman MM, Davis MJ, Wulff H, Hill MA, Braun AP. Alpha1 -adrenergic stimulation selectively enhances endothelium-mediated vasodilation in rat cremaster arteries. Physiol Rep. 2018 May; 6(9):e13703. PMID: 29756401.
      View in: PubMed
    4. Lee KSS, Liu JY, Wagner KM, Pakhomova S, Dong H, Morisseau C, Fu SH, Yang J, Wang P, Ulu A, Mate CA, Nguyen LV, Hwang SH, Edin ML, Mara AA, Wulff H, Newcomer ME, Zeldin DC, Hammock BD. Correction to Optimized Inhibitors of Soluble Epoxide Hydrolase Improve in Vitro Target Residence Time and in Vivo Efficacy. J Med Chem. 2018 May 10; 61(9):4271. PMID: 29701466.
      View in: PubMed
    5. Bednenko J, Harriman R, Mariën L, Nguyen HM, Agrawal A, Papoyan A, Bisharyan Y, Cardarelli J, Cassidy-Hanley D, Clark T, Pedersen D, Abdiche Y, Harriman W, van der Woning B, de Haard H, Collarini E, Wulff H, Colussi P. A multiplatform strategy for the discovery of conventional monoclonal antibodies that inhibit the voltage-gated potassium channel Kv1.3. MAbs. 2018 Mar 01; 1-15. PMID: 29494279.
      View in: PubMed
    6. Maezawa I, Nguyen HM, Di Lucente J, Jenkins DP, Singh V, Hilt S, Kim K, Rangaraju S, Levey AI, Wulff H, Jin LW. Kv1.3 inhibition as a potential microglia-targeted therapy for Alzheimer's disease: preclinical proof of concept. Brain. 2018 Feb 01; 141(2):596-612. PMID: 29272333.
      View in: PubMed
    7. Bushart DD, Chopra R, Singh V, Murphy GG, Wulff H, Shakkottai VG. Targeting potassium channels to treat cerebellar ataxia. Ann Clin Transl Neurol. 2018 Mar; 5(3):297-314. PMID: 29560375.
      View in: PubMed
    8. Brown BM, Pressley B, Wulff H. KCa3.1 Channel Modulators as Potential Therapeutic Compounds for Glioblastoma. Curr Neuropharmacol. 2018; 16(5):618-626. PMID: 28676010.
      View in: PubMed
    9. Chen YJ, Nguyen HM, Maezawa I, Jin LW, Wulff H. Inhibition of the potassium channel Kv1.3 reduces infarction and inflammation in ischemic stroke. Ann Clin Transl Neurol. 2018 Feb; 5(2):147-161. PMID: 29468176.
      View in: PubMed
    10. Nam YW, Orfali R, Liu T, Yu K, Cui M, Wulff H, Zhang M. Structural insights into the potency of SK channel positive modulators. Sci Rep. 2017 Dec 07; 7(1):17178. PMID: 29214998.
      View in: PubMed
    11. Pillozzi S, D'Amico M, Bartoli G, Gasparoli L, Petroni G, Crociani O, Marzo T, Guerriero A, Messori L, Severi M, Udisti R, Wulff H, Chandy KG, Becchetti A, Arcangeli A. The combined activation of KCa3.1 and inhibition of Kv11.1/hERG1 currents contribute to overcome Cisplatin resistance in colorectal cancer cells. Br J Cancer. 2018 Jan; 118(2):200-212. PMID: 29161243.
      View in: PubMed
    12. Pressly B, Nguyen HM, Wulff H. GABAA receptor subtype selectivity of the proconvulsant rodenticide TETS. Arch Toxicol. 2018 Feb; 92(2):833-844. PMID: 29038840.
      View in: PubMed
    13. Brown BM, Shim H, Wulff H. Are there superagonists for calcium-activated potassium channels? Channels (Austin). 2017 Nov 02; 11(6):504-506. PMID: 28876978.
      View in: PubMed
    14. Brown BM, Shim H, Zhang M, Yarov-Yarovoy V, Wulff H. Structural Determinants for the Selectivity of the Positive KCa3.1 Gating Modulator 5-Methylnaphtho[2,1-d]oxazol-2-amine (SKA-121). Mol Pharmacol. 2017 Oct; 92(4):469-480. PMID: 28760780.
      View in: PubMed
    15. Mengeling BJ, Wei Y, Dobrawa LN, Streekstra M, Louisse J, Singh V, Singh L, Lein PJ, Wulff H, Murk AJ, Furlow JD. A multi-tiered, in vivo, quantitative assay suite for environmental disruptors of thyroid hormone signaling. Aquat Toxicol. 2017 Sep; 190:1-10. PMID: 28662416.
      View in: PubMed
    16. Barnych B, Vasylieva N, Joseph T, Hulsizer S, Nguyen HM, Cajka T, Pessah I, Wulff H, Gee SJ, Hammock BD. Development of Tetramethylenedisulfotetramine (TETS) Hapten Library: Synthesis, Electrophysiological Studies, and Immune Response in Rabbits. Chemistry. 2017 Jun 22; 23(35):8466-8472. PMID: 28411375.
      View in: PubMed
    17. Nik AM, Pressly B, Singh V, Antrobus S, Hulsizer S, Rogawski MA, Wulff H, Pessah IN. Rapid Throughput Analysis of GABAA Receptor Subtype Modulators and Blockers Using DiSBAC1(3) Membrane Potential Red Dye. Mol Pharmacol. 2017 Jul; 92(1):88-99. PMID: 28428226.
      View in: PubMed
    18. Chen H, Streifel KM, Singh V, Yang D, Mangini L, Wulff H, Lein PJ. From the Cover: BDE-47 and BDE-49 Inhibit Axonal Growth in Primary Rat Hippocampal Neuron-Glia Co-Cultures via Ryanodine Receptor-Dependent Mechanisms. Toxicol Sci. 2017 04 01; 156(2):375-386. PMID: 28003438.
      View in: PubMed
    19. Vasylieva N, Barnych B, Wan D, El-Sheikh EA, Nguyen HM, Wulff H, McMahen R, Strynar M, Gee SJ, Hammock BD. Hydroxy-fipronil is a new urinary biomarker of exposure to fipronil. Environ Int. 2017 06; 103:91-98. PMID: 28343720.
      View in: PubMed
    20. Nguyen HM, Blomster LV, Christophersen P, Wulff H. Potassium channel expression and function in microglia: Plasticity and possible species variations. Channels (Austin). 2017 Jul 04; 11(4):305-315. PMID: 28277939.
      View in: PubMed
    21. Nguyen HM, Singh V, Pressly B, Jenkins DP, Wulff H, Yarov-Yarovoy V. Structural Insights into the Atomistic Mechanisms of Action of Small Molecule Inhibitors Targeting the KCa3.1 Channel Pore. Mol Pharmacol. 2017 04; 91(4):392-402. PMID: 28126850.
      View in: PubMed
    22. Hilt S, Tang T, Walton JH, Budamagunta M, Maezawa I, Kálai T, Hideg K, Singh V, Wulff H, Gong Q, Jin LW, Louie A, Voss JC. A Metal-Free Method for Producing MRI Contrast at Amyloid-ß. J Alzheimers Dis. 2017; 55(4):1667-1681. PMID: 27911291.
      View in: PubMed
    23. Kaczmarek LK, Aldrich RW, Chandy KG, Grissmer S, Wei AD, Wulff H. International Union of Basic and Clinical Pharmacology. C. Nomenclature and Properties of Calcium-Activated and Sodium-Activated Potassium Channels. Pharmacol Rev. 2017 Jan; 69(1):1-11. PMID: 28267675.
      View in: PubMed
    24. Nguyen HM, Grössinger EM, Horiuchi M, Davis KW, Jin LW, Maezawa I, Wulff H. Differential Kv1.3, KCa3.1, and Kir2.1 expression in "classically" and "alternatively" activated microglia. Glia. 2017 01; 65(1):106-121. PMID: 27696527.
      View in: PubMed
    25. Pessah IN, Rogawski MA, Tancredi DJ, Wulff H, Zolkowska D, Bruun DA, Hammock BD, Lein PJ. Models to identify treatments for the acute and persistent effects of seizure-inducing chemical threat agents. Ann N Y Acad Sci. 2016 08; 1378(1):124-136. PMID: 27467073.
      View in: PubMed
    26. Ulu A, Inceoglu B, Yang J, Singh V, Vito S, Wulff H, Hammock BD. Inhibition of soluble epoxide hydrolase as a novel approach to high dose diazepam induced hypotension. J Clin Toxicol. 2016 Jun; 6(3). PMID: 28255523.
      View in: PubMed
    27. D'Alessandro G, Grimaldi A, Chece G, Porzia A, Esposito V, Santoro A, Salvati M, Mainiero F, Ragozzino D, Di Angelantonio S, Wulff H, Catalano M, Limatola C. KCa3.1 channel inhibition sensitizes malignant gliomas to temozolomide treatment. Oncotarget. 2016 May 24; 7(21):30781-96. PMID: 27096953.
      View in: PubMed
    28. Glaser N, Little C, Lo W, Cohen M, Tancredi D, Wulff H, O'Donnell M. Treatment with the KCa3.1 inhibitor TRAM-34 during diabetic ketoacidosis reduces inflammatory changes in the brain. Pediatr Diabetes. 2017 Aug; 18(5):356-366. PMID: 27174668.
      View in: PubMed
    29. Raychaudhuri SK, Wulff H, Raychaudhuri SP. KCa3.1(-/-) Mice Do Not Develop CIA: Regulatory Role for KCa3.1 in Autoimmune Arthritis. J Cell Physiol. 2016 Nov; 231(11):2313-4. PMID: 26910182.
      View in: PubMed
    30. Oliván-Viguera A, Valero MS, Pinilla E, Amor S, García-Villalón ÁL, Coleman N, Laría C, Calvín-Tienza V, García-Otín ÁL, Fernández-Fernández JM, Murillo MD, Gálvez JA, Díaz-de-Villegas MD, Badorrey R, Simonsen U, Rivera L, Wulff H, Köhler R. Vascular Reactivity Profile of Novel KCa 3.1-Selective Positive-Gating Modulators in the Coronary Vascular Bed. Basic Clin Pharmacol Toxicol. 2016 Aug; 119(2):184-92. PMID: 26821335.
      View in: PubMed
    31. Singh L, Pressly B, Mengeling BJ, Fettinger JC, Furlow JD, Lein PJ, Wulff H, Singh V. Chasing the Elusive Benzofuran Impurity of the THR Antagonist NH-3: Synthesis, Isotope Labeling, and Biological Activity. J Org Chem. 2016 Mar 04; 81(5):1870-6. PMID: 26849160.
      View in: PubMed
    32. Gao J, Naughton SX, Wulff H, Singh V, Beck WD, Magrane J, Thomas B, Kaidery NA, Hernandez CM, Terry AV. Diisopropylfluorophosphate Impairs the Transport of Membrane-Bound Organelles in Rat Cortical Axons. J Pharmacol Exp Ther. 2016 Mar; 356(3):645-55. PMID: 26718240; PMCID: PMC4767389 [Available on 03/01/17].
      View in: PubMed, PubMed Central
    33. Wulff H, Christophersen P. Recent developments in ion channel pharmacology. Channels (Austin). 2015; 9(6):335. PMID: 26646476; PMCID: PMC4850044 [Available on 11/17/16].
      View in: PubMed, PubMed Central
    34. Chen YJ, Nguyen HM, Maezawa I, Grössinger EM, Garing AL, Köhler R, Jin LW, Wulff H. The potassium channel KCa3.1 constitutes a pharmacological target for neuroinflammation associated with ischemia/reperfusion stroke. J Cereb Blood Flow Metab. 2016 Dec; 36(12):2146-2161. PMID: 26661208.
      View in: PubMed
    35. Hong L, Singh V, Wulff H, Tombola F. Interrogation of the intersubunit interface of the open Hv1 proton channel with a probe of allosteric coupling. Sci Rep. 2015 Sep 14; 5:14077. PMID: 26365828; PMCID: PMC4568520.
      View in: PubMed, PubMed Central
    36. Dell'Orco JM, Wasserman AH, Chopra R, Ingram MA, Hu YS, Singh V, Wulff H, Opal P, Orr HT, Shakkottai VG. Neuronal Atrophy Early in Degenerative Ataxia Is a Compensatory Mechanism to Regulate Membrane Excitability. J Neurosci. 2015 Aug 12; 35(32):11292-307. PMID: 26269637; PMCID: PMC4532759.
      View in: PubMed, PubMed Central
    37. Mishra RC, Mitchell JR, Gibbons-Kroeker C, Wulff H, Belenkie I, Tyberg JV, Braun AP. A pharmacologic activator of endothelial KCa channels increases systemic conductance and reduces arterial pressure in an anesthetized pig model. Vascul Pharmacol. 2016 Apr; 79:24-31. PMID: 26239885.
      View in: PubMed
    38. Christophersen P, Wulff H. Pharmacological gating modulation of small- and intermediate-conductance Ca(2+)-activated K(+) channels (KCa2.x and KCa3.1). Channels (Austin). 2015; 9(6):336-43. PMID: 26217968; PMCID: PMC4850045.
      View in: PubMed, PubMed Central
    39. Mishra RC, Wulff H, Hill MA, Braun AP. Inhibition of Myogenic Tone in Rat Cremaster and Cerebral Arteries by SKA-31, an Activator of Endothelial KCa2.3 and KCa3.1 Channels. J Cardiovasc Pharmacol. 2015 Jul; 66(1):118-27. PMID: 25815673; PMCID: PMC4500737.
      View in: PubMed, PubMed Central
    40. Roach KM, Feghali-Bostwick C, Wulff H, Amrani Y, Bradding P. Human lung myofibroblast TGFß1-dependent Smad2/3 signalling is Ca(2+)-dependent and regulated by KCa3.1 K(+) channels. Fibrogenesis Tissue Repair. 2015; 8:5. PMID: 25829947; PMCID: PMC4379608.
      View in: PubMed, PubMed Central
    41. Jin LW, Horiuchi M, Wulff H, Liu XB, Cortopassi GA, Erickson JD, Maezawa I. Dysregulation of glutamine transporter SNAT1 in Rett syndrome microglia: a mechanism for mitochondrial dysfunction and neurotoxicity. J Neurosci. 2015 Feb 11; 35(6):2516-29. PMID: 25673846; PMCID: PMC4323531.
      View in: PubMed, PubMed Central
    42. Cao Z, Zou X, Cui Y, Hulsizer S, Lein PJ, Wulff H, Pessah IN. Rapid throughput analysis demonstrates that chemicals with distinct seizurogenic mechanisms differentially alter Ca2+ dynamics in networks formed by hippocampal neurons in culture. Mol Pharmacol. 2015 Apr; 87(4):595-605. PMID: 25583085; PMCID: PMC4366799.
      View in: PubMed, PubMed Central
    43. Coleman N, Nguyen HM, Cao Z, Brown BM, Jenkins DP, Zolkowska D, Chen YJ, Tanaka BS, Goldin AL, Rogawski MA, Pessah IN, Wulff H. The riluzole derivative 2-amino-6-trifluoromethylthio-benzothiazole (SKA-19), a mixed KCa2 activator and NaV blocker, is a potent novel anticonvulsant. Neurotherapeutics. 2015 Jan; 12(1):234-49. PMID: 25256961; PMCID: PMC4322077.
      View in: PubMed, PubMed Central
    44. Roach KM, Wulff H, Feghali-Bostwick C, Amrani Y, Bradding P. Increased constitutive aSMA and Smad2/3 expression in idiopathic pulmonary fibrosis myofibroblasts is KCa3.1-dependent. Respir Res. 2014 Dec 05; 15:155. PMID: 25476248; PMCID: PMC4263015.
      View in: PubMed, PubMed Central
    45. Chen YJ, Wallace BK, Yuen N, Jenkins DP, Wulff H, O'Donnell ME. Blood-brain barrier KCa3.1 channels: evidence for a role in brain Na uptake and edema in ischemic stroke. Stroke. 2015 Jan; 46(1):237-44. PMID: 25477223; PMCID: PMC4276511.
      View in: PubMed, PubMed Central
    46. Oliván-Viguera A, Valero MS, Coleman N, Brown BM, Laría C, Murillo MD, Gálvez JA, Díaz-de-Villegas MD, Wulff H, Badorrey R, Köhler R. A novel pan-negative-gating modulator of KCa2/3 channels, fluoro-di-benzoate, RA-2, inhibits endothelium-derived hyperpolarization-type relaxation in coronary artery and produces bradycardia in vivo. Mol Pharmacol. 2015 Feb; 87(2):338-48. PMID: 25468883; PMCID: PMC4293453.
      View in: PubMed, PubMed Central
    47. Waeckel L, Badier-Commander C, Damery T, Köhler R, Sansilvestri-Morel P, Simonet S, Vayssettes-Courchay C, Wulff H, Félétou M. Vascular dysfunctions in the isolated aorta of double-transgenic hypertensive mice developing aortic aneurysm. Pflugers Arch. 2015 Sep; 467(9):1945-63. PMID: 25385304.
      View in: PubMed
    48. Kundu-Raychaudhuri S, Chen YJ, Wulff H, Raychaudhuri SP. Kv1.3 in psoriatic disease: PAP-1, a small molecule inhibitor of Kv1.3 is effective in the SCID mouse psoriasis--xenograft model. J Autoimmun. 2014 Dec; 55:63-72. PMID: 25175978; PMCID: PMC4398058.
      View in: PubMed, PubMed Central
    49. Sahdeo S, Scott BD, McMackin MZ, Jasoliya M, Brown B, Wulff H, Perlman SL, Pook MA, Cortopassi GA. Dyclonine rescues frataxin deficiency in animal models and buccal cells of patients with Friedreich's ataxia. Hum Mol Genet. 2014 Dec 20; 23(25):6848-62. PMID: 25113747; PMCID: PMC4245046.
      View in: PubMed, PubMed Central
    50. Lee KS, Liu JY, Wagner KM, Pakhomova S, Dong H, Morisseau C, Fu SH, Yang J, Wang P, Ulu A, Mate CA, Nguyen LV, Hwang SH, Edin ML, Mara AA, Wulff H, Newcomer ME, Zeldin DC, Hammock BD. Optimized inhibitors of soluble epoxide hydrolase improve in vitro target residence time and in vivo efficacy. J Med Chem. 2014 Aug 28; 57(16):7016-30. PMID: 25079952.
      View in: PubMed
    51. Coleman N, Brown BM, Oliván-Viguera A, Singh V, Olmstead MM, Valero MS, Köhler R, Wulff H. New positive Ca2+-activated K+ channel gating modulators with selectivity for KCa3.1. Mol Pharmacol. 2014 Sep; 86(3):342-57. PMID: 24958817; PMCID: PMC4152908.
      View in: PubMed, PubMed Central
    52. Waeckel L, Bertin F, Clavreul N, Damery T, Köhler R, Paysant J, Sansilvestri-Morel P, Simonet S, Vayssettes-Courchay C, Wulff H, Verbeuren TJ, Félétou M. Preserved regulation of renal perfusion pressure by small and intermediate conductance KCa channels in hypertensive mice with or without renal failure. Pflugers Arch. 2015 Apr; 467(4):817-31. PMID: 24903240.
      View in: PubMed
    53. Chhabra S, Chang SC, Nguyen HM, Huq R, Tanner MR, Londono LM, Estrada R, Dhawan V, Chauhan S, Upadhyay SK, Gindin M, Hotez PJ, Valenzuela JG, Mohanty B, Swarbrick JD, Wulff H, Iadonato SP, Gutman GA, Beeton C, Pennington MW, Norton RS, Chandy KG. Kv1.3 channel-blocking immunomodulatory peptides from parasitic worms: implications for autoimmune diseases. FASEB J. 2014 Sep; 28(9):3952-64. PMID: 24891519; PMCID: PMC4139903.
      View in: PubMed, PubMed Central
    54. Koch Hansen L, Sevelsted-Møller L, Rabjerg M, Larsen D, Hansen TP, Klinge L, Wulff H, Knudsen T, Kjeldsen J, Köhler R. Expression of T-cell KV1.3 potassium channel correlates with pro-inflammatory cytokines and disease activity in ulcerative colitis. J Crohns Colitis. 2014 Nov; 8(11):1378-91. PMID: 24793818; PMCID: PMC4216648.
      View in: PubMed, PubMed Central
    55. Mishra RC, Wulff H, Cole WC, Braun AP. A pharmacologic activator of endothelial KCa channels enhances coronary flow in the hearts of type 2 diabetic rats. J Mol Cell Cardiol. 2014 Jul; 72:364-73. PMID: 24787473.
      View in: PubMed
    56. Luna-Cancalon K, Sikora KM, Pappas SS, Singh V, Wulff H, Paulson HL, Burmeister M, Shakkottai VG. Alterations in cerebellar physiology are associated with a stiff-legged gait in Atcay(ji-hes) mice. Neurobiol Dis. 2014 Jul; 67:140-8. PMID: 24727095; PMCID: PMC4059535.
      View in: PubMed, PubMed Central
    57. Cao Z, Cui Y, Nguyen HM, Jenkins DP, Wulff H, Pessah IN. Nanomolar bifenthrin alters synchronous Ca2+ oscillations and cortical neuron development independent of sodium channel activity. Mol Pharmacol. 2014 Apr; 85(4):630-9. PMID: 24482397; PMCID: PMC3965893.
      View in: PubMed, PubMed Central
    58. Roach KM, Roach KM, Duffy SM, Coward W, Feghali-Bostwick C, Wulff H, Bradding P. The K+ channel KCa3.1 as a novel target for idiopathic pulmonary fibrosis. PLoS One. 2013; 8(12):e85244. PMID: 24392001; PMCID: PMC3877378.
      View in: PubMed, PubMed Central
    59. Chen YJ, Lam J, Gregory CR, Schrepfer S, Wulff H. The Ca²?-activated K? channel KCa3.1 as a potential new target for the prevention of allograft vasculopathy. PLoS One. 2013; 8(11):e81006. PMID: 24312257; PMCID: PMC3843675.
      View in: PubMed, PubMed Central
    60. Jenkins DP, Yu W, Brown BM, Løjkner LD, Wulff H. Development of a QPatch automated electrophysiology assay for identifying KCa3.1 inhibitors and activators. Assay Drug Dev Technol. 2013 Nov-Dec; 11(9-10):551-60. PMID: 24351043; PMCID: PMC3870577.
      View in: PubMed, PubMed Central
    61. Koshy S, Wu D, Hu X, Tajhya RB, Huq R, Khan FS, Pennington MW, Wulff H, Yotnda P, Beeton C. Blocking KCa3.1 channels increases tumor cell killing by a subpopulation of human natural killer lymphocytes. PLoS One. 2013; 8(10):e76740. PMID: 24146918; PMCID: PMC3795664.
      View in: PubMed, PubMed Central
    62. Radtke J, Schmidt K, Wulff H, Köhler R, de Wit C. Activation of KCa3.1 by SKA-31 induces arteriolar dilatation and lowers blood pressure in normo- and hypertensive connexin40-deficient mice. Br J Pharmacol. 2013 Sep; 170(2):293-303. PMID: 23734697; PMCID: PMC3834754.
      View in: PubMed, PubMed Central
    63. Wulff H, Yarov-Yarovoy V. Channels: Sticking to nooks and crannies. Nat Chem Biol. 2013 Aug; 9(8):473-4. PMID: 23868316.
      View in: PubMed
    64. Lam J, Coleman N, Garing AL, Wulff H. The therapeutic potential of small-conductance KCa2 channels in neurodegenerative and psychiatric diseases. Expert Opin Ther Targets. 2013 Oct; 17(10):1203-20. PMID: 23883298; PMCID: PMC3778119.
      View in: PubMed, PubMed Central
    65. Van Der Velden J, Sum G, Barker D, Koumoundouros E, Barcham G, Wulff H, Castle N, Bradding P, Snibson K. K(Ca)3.1 channel-blockade attenuates airway pathophysiology in a sheep model of chronic asthma. PLoS One. 2013; 8(6):e66886. PMID: 23826167; PMCID: PMC3691218.
      View in: PubMed, PubMed Central
    66. Bi D, Toyama K, Lemaître V, Takai J, Fan F, Jenkins DP, Wulff H, Gutterman DD, Park F, Miura H. The intermediate conductance calcium-activated potassium channel KCa3.1 regulates vascular smooth muscle cell proliferation via controlling calcium-dependent signaling. J Biol Chem. 2013 May 31; 288(22):15843-53. PMID: 23609438; PMCID: PMC3668741.
      View in: PubMed, PubMed Central
    67. Bradding P, Wulff H. Ion channels. Thorax. 2013 Oct; 68(10):974-7. PMID: 23564342.
      View in: PubMed
    68. Oliván-Viguera A, Valero MS, Murillo MD, Wulff H, García-Otín AL, Arbonés-Mainar JM, Köhler R. Novel phenolic inhibitors of small/intermediate-conductance Ca²?-activated K? channels, KCa3.1 and KCa2.3. PLoS One. 2013; 8(3):e58614. PMID: 23516517; PMCID: PMC3597730.
      View in: PubMed, PubMed Central
    69. Wulff H, Köhler R. Endothelial small-conductance and intermediate-conductance KCa channels: an update on their pharmacology and usefulness as cardiovascular targets. J Cardiovasc Pharmacol. 2013 Feb; 61(2):102-12. PMID: 23107876; PMCID: PMC3565027.
      View in: PubMed, PubMed Central
    70. Hua X, Deuse T, Chen YJ, Wulff H, Stubbendorff M, Köhler R, Miura H, Länger F, Reichenspurner H, Robbins RC, Schrepfer S. The potassium channel KCa3.1 as new therapeutic target for the prevention of obliterative airway disease. Transplantation. 2013 Jan 27; 95(2):285-92. PMID: 23325003; PMCID: PMC3777777.
      View in: PubMed, PubMed Central
    71. Jin BE, Wulff H, Widdicombe JH, Zheng J, Bers DM, Puglisi JL. A simple device to illustrate the Einthoven triangle. Adv Physiol Educ. 2012 Dec; 36(4):319-24. PMID: 23209014; PMCID: PMC3776430.
      View in: PubMed, PubMed Central
    72. Girodet PO, Ozier A, Carvalho G, Ilina O, Ousova O, Gadeau AP, Begueret H, Wulff H, Marthan R, Bradding P, Berger P. Ca(2+)-activated K(+) channel-3.1 blocker TRAM-34 attenuates airway remodeling and eosinophilia in a murine asthma model. Am J Respir Cell Mol Biol. 2013 Feb; 48(2):212-9. PMID: 23204391; PMCID: PMC4035224.
      View in: PubMed, PubMed Central
    73. Mishra RC, Belke D, Wulff H, Braun AP. SKA-31, a novel activator of SK(Ca) and IK(Ca) channels, increases coronary flow in male and female rat hearts. Cardiovasc Res. 2013 Feb 01; 97(2):339-48. PMID: 23118129; PMCID: PMC3543990.
      View in: PubMed, PubMed Central
    74. Lambertsen KL, Gramsbergen JB, Sivasaravanaparan M, Ditzel N, Sevelsted-Møller LM, Oliván-Viguera A, Rabjerg M, Wulff H, Köhler R. Genetic KCa3.1-deficiency produces locomotor hyperactivity and alterations in cerebral monoamine levels. PLoS One. 2012; 7(10):e47744. PMID: 23077667; PMCID: PMC3471871.
      View in: PubMed, PubMed Central
    75. Nguyen W, Howard BL, Jenkins DP, Wulff H, Thompson PE, Manallack DT. Structure-activity relationship exploration of Kv1.3 blockers based on diphenoxylate. Bioorg Med Chem Lett. 2012 Dec 01; 22(23):7106-9. PMID: 23084278; PMCID: PMC3664202.
      View in: PubMed, PubMed Central
    76. Bodendiek SB, Rubinos C, Trelles MP, Coleman N, Jenkins DP, Wulff H, Srinivas M. Triarylmethanes, a new class of cx50 inhibitors. Front Pharmacol. 2012; 3:106. PMID: 22685432; PMCID: PMC3368247.
      View in: PubMed, PubMed Central
    77. Maezawa I, Jenkins DP, Jin BE, Wulff H. Microglial KCa3.1 Channels as a Potential Therapeutic Target for Alzheimer's Disease. Int J Alzheimers Dis. 2012; 2012:868972. PMID: 22675649; PMCID: PMC3364551.
      View in: PubMed, PubMed Central
    78. Maezawa I, Calafiore M, Wulff H, Jin LW. Does microglial dysfunction play a role in autism and Rett syndrome? Neuron Glia Biol. 2011 Feb; 7(1):85-97. PMID: 22717189; PMCID: PMC4976478.
      View in: PubMed, PubMed Central
    79. Vandendriessche T, Kopljar I, Jenkins DP, Diego-Garcia E, Abdel-Mottaleb Y, Vermassen E, Clynen E, Schoofs L, Wulff H, Snyders D, Tytgat J. Purification, molecular cloning and functional characterization of HelaTx1 (Heterometrus laoticus): the first member of a new ?-KTX subfamily. Biochem Pharmacol. 2012 May 01; 83(9):1307-17. PMID: 22305749; PMCID: PMC3644210.
      View in: PubMed, PubMed Central
    80. Damkjaer M, Nielsen G, Bodendiek S, Staehr M, Gramsbergen JB, de Wit C, Jensen BL, Simonsen U, Bie P, Wulff H, Köhler R. Pharmacological activation of KCa3.1/KCa2.3 channels produces endothelial hyperpolarization and lowers blood pressure in conscious dogs. Br J Pharmacol. 2012 Jan; 165(1):223-34. PMID: 21699504; PMCID: PMC3252979.
      View in: PubMed, PubMed Central
    81. Lam J, Wulff H. The Lymphocyte Potassium Channels Kv1.3 and KCa3.1 as Targets for Immunosuppression. Drug Dev Res. 2011 Nov; 72(7):573-584. PMID: 22241939.
      View in: PubMed
    82. Shakkottai VG, do Carmo Costa M, Dell'Orco JM, Sankaranarayanan A, Wulff H, Paulson HL. Early changes in cerebellar physiology accompany motor dysfunction in the polyglutamine disease spinocerebellar ataxia type 3. J Neurosci. 2011 Sep 07; 31(36):13002-14. PMID: 21900579; PMCID: PMC3170039.
      View in: PubMed, PubMed Central
    83. Chi V, Pennington MW, Norton RS, Tarcha EJ, Londono LM, Sims-Fahey B, Upadhyay SK, Lakey JT, Iadonato S, Wulff H, Beeton C, Chandy KG. Development of a sea anemone toxin as an immunomodulator for therapy of autoimmune diseases. Toxicon. 2012 Mar 15; 59(4):529-46. PMID: 21867724; PMCID: PMC3397671.
      View in: PubMed, PubMed Central
    84. Chen YJ, Raman G, Bodendiek S, O'Donnell ME, Wulff H. The KCa3.1 blocker TRAM-34 reduces infarction and neurological deficit in a rat model of ischemia/reperfusion stroke. J Cereb Blood Flow Metab. 2011 Dec; 31(12):2363-74. PMID: 21750563; PMCID: PMC3323185.
      View in: PubMed, PubMed Central
    85. Jenkins DP, Strøbæk D, Hougaard C, Jensen ML, Hummel R, Sørensen US, Christophersen P, Wulff H. Negative gating modulation by (R)-N-(benzimidazol-2-yl)-1,2,3,4-tetrahydro-1-naphthylamine (NS8593) depends on residues in the inner pore vestibule: pharmacological evidence of deep-pore gating of K(Ca)2 channels. Mol Pharmacol. 2011 Jun; 79(6):899-909. PMID: 21363929; PMCID: PMC3102549.
      View in: PubMed, PubMed Central
    86. Maezawa I, Zimin PI, Wulff H, Jin LW. Amyloid-beta protein oligomer at low nanomolar concentrations activates microglia and induces microglial neurotoxicity. J Biol Chem. 2011 Feb 04; 286(5):3693-706. PMID: 20971854; PMCID: PMC3030372.
      View in: PubMed, PubMed Central
    87. Wulff H. Spiro azepane-oxazolidinones as Kv1.3 potassium channel blockers: WO2010066840. Expert Opin Ther Pat. 2010 Dec; 20(12):1759-65. PMID: 20954790; PMCID: PMC2988097.
      View in: PubMed, PubMed Central
    88. Zimin PI, Garic B, Bodendiek SB, Mahieux C, Wulff H, Zhorov BS. Potassium channel block by a tripartite complex of two cationophilic ligands and a potassium ion. Mol Pharmacol. 2010 Oct; 78(4):588-99. PMID: 20601455; PMCID: PMC2981387.
      View in: PubMed, PubMed Central
    89. Wulff H, Castle NA. Therapeutic potential of KCa3.1 blockers: recent advances and promising trends. Expert Rev Clin Pharmacol. 2010 May; 3(3):385-96. PMID: 22111618; PMCID: PMC3347644.
      View in: PubMed, PubMed Central
    90. Al-Ghananeem AM, Abbassi M, Shrestha S, Raman G, Wulff H, Pereira L, Ansari A. Formulation-based approach to support early drug discovery and development efforts: a case study with enteric microencapsulation dosage form development for a triarylmethane derivative TRAM-34; a novel potential immunosuppressant. Drug Dev Ind Pharm. 2010 May; 36(5):563-9. PMID: 19929567; PMCID: PMC3337761.
      View in: PubMed, PubMed Central
    91. Köhler R, Kaistha BP, Wulff H. Vascular KCa-channels as therapeutic targets in hypertension and restenosis disease. Expert Opin Ther Targets. 2010 Feb; 14(2):143-55. PMID: 20055714; PMCID: PMC3644209.
      View in: PubMed, PubMed Central
    92. Di L, Srivastava S, Zhdanova O, Ding Y, Li Z, Wulff H, Lafaille M, Skolnik EY. Inhibition of the K+ channel KCa3.1 ameliorates T cell-mediated colitis. Proc Natl Acad Sci U S A. 2010 Jan 26; 107(4):1541-6. PMID: 20080610; PMCID: PMC2824388.
      View in: PubMed, PubMed Central
    93. Wulff H, Castle NA, Pardo LA. Voltage-gated potassium channels as therapeutic targets. Nat Rev Drug Discov. 2009 Dec; 8(12):982-1001. PMID: 19949402; PMCID: PMC2790170.
      View in: PubMed, PubMed Central
    94. Grgic I, Kiss E, Kaistha BP, Busch C, Kloss M, Sautter J, Müller A, Kaistha A, Schmidt C, Raman G, Wulff H, Strutz F, Gröne HJ, Köhler R, Hoyer J. Renal fibrosis is attenuated by targeted disruption of KCa3.1 potassium channels. Proc Natl Acad Sci U S A. 2009 Aug 25; 106(34):14518-23. PMID: 19706538; PMCID: PMC2726862.
      View in: PubMed, PubMed Central
    95. Bradding P, Wulff H. The K+ channels K(Ca)3.1 and K(v)1.3 as novel targets for asthma therapy. Br J Pharmacol. 2009 Aug; 157(8):1330-9. PMID: 19681865; PMCID: PMC2765317.
      View in: PubMed, PubMed Central
    96. Srivastava S, Di L, Zhdanova O, Li Z, Vardhana S, Wan Q, Yan Y, Varma R, Backer J, Wulff H, Dustin ML, Skolnik EY. The class II phosphatidylinositol 3 kinase C2beta is required for the activation of the K+ channel KCa3.1 and CD4 T-cells. Mol Biol Cell. 2009 Sep; 20(17):3783-91. PMID: 19587117; PMCID: PMC2735477.
      View in: PubMed, PubMed Central
    97. Brähler S, Kaistha A, Schmidt VJ, Wölfle SE, Busch C, Kaistha BP, Kacik M, Hasenau AL, Grgic I, Si H, Bond CT, Adelman JP, Wulff H, de Wit C, Hoyer J, Köhler R. Genetic deficit of SK3 and IK1 channels disrupts the endothelium-derived hyperpolarizing factor vasodilator pathway and causes hypertension. Circulation. 2009 May 05; 119(17):2323-32. PMID: 19380617.
      View in: PubMed
    98. Bodendiek SB, Mahieux C, Hänsel W, Wulff H. 4-Phenoxybutoxy-substituted heterocycles--a structure-activity relationship study of blockers of the lymphocyte potassium channel Kv1.3. Eur J Med Chem. 2009 May; 44(5):1838-52. PMID: 19056148; PMCID: PMC2662044.
      View in: PubMed, PubMed Central
    99. Sankaranarayanan A, Raman G, Busch C, Schultz T, Zimin PI, Hoyer J, Köhler R, Wulff H. Naphtho[1,2-d]thiazol-2-ylamine (SKA-31), a new activator of KCa2 and KCa3.1 potassium channels, potentiates the endothelium-derived hyperpolarizing factor response and lowers blood pressure. Mol Pharmacol. 2009 Feb; 75(2):281-95. PMID: 18955585; PMCID: PMC2635097.
      View in: PubMed, PubMed Central
    100. Srivastava S, Zhdanova O, Di L, Li Z, Albaqumi M, Wulff H, Skolnik EY. Protein histidine phosphatase 1 negatively regulates CD4 T cells by inhibiting the K+ channel KCa3.1. Proc Natl Acad Sci U S A. 2008 Sep 23; 105(38):14442-6. PMID: 18796614; PMCID: PMC2538450.
      View in: PubMed, PubMed Central
    101. Toyama K, Wulff H, Chandy KG, Azam P, Raman G, Saito T, Fujiwara Y, Mattson DL, Das S, Melvin JE, Pratt PF, Hatoum OA, Gutterman DD, Harder DR, Miura H. The intermediate-conductance calcium-activated potassium channel KCa3.1 contributes to atherogenesis in mice and humans. J Clin Invest. 2008 Sep; 118(9):3025-37. PMID: 18688283; PMCID: PMC2496961.
      View in: PubMed, PubMed Central
    102. Wulff H. New light on the "old" chloride channel blocker DIDS. ACS Chem Biol. 2008 Jul 18; 3(7):399-401. PMID: 18642798.
      View in: PubMed
    103. Albaqumi M, Srivastava S, Li Z, Zhdnova O, Wulff H, Itani O, Wallace DP, Skolnik EY. KCa3.1 potassium channels are critical for cAMP-dependent chloride secretion and cyst growth in autosomal-dominant polycystic kidney disease. Kidney Int. 2008 Sep; 74(6):740-9. PMID: 18547995.
      View in: PubMed
    104. Wulff H, Zhorov BS. K+ channel modulators for the treatment of neurological disorders and autoimmune diseases. Chem Rev. 2008 May; 108(5):1744-73. PMID: 18476673; PMCID: PMC2714671.
      View in: PubMed, PubMed Central
    105. Wulff H, Pennington M. Targeting effector memory T-cells with Kv1.3 blockers. Curr Opin Drug Discov Devel. 2007 Jul; 10(4):438-45. PMID: 17659485.
      View in: PubMed
    106. Azam P, Sankaranarayanan A, Homerick D, Griffey S, Wulff H. Targeting effector memory T cells with the small molecule Kv1.3 blocker PAP-1 suppresses allergic contact dermatitis. J Invest Dermatol. 2007 Jun; 127(6):1419-29. PMID: 17273162; PMCID: PMC1929164.
      View in: PubMed, PubMed Central
    107. Moritoki Y, Lian ZX, Wulff H, Yang GX, Chuang YH, Lan RY, Ueno Y, Ansari AA, Coppel RL, Mackay IR, Gershwin ME. AMA production in primary biliary cirrhosis is promoted by the TLR9 ligand CpG and suppressed by potassium channel blockers. Hepatology. 2007 Feb; 45(2):314-22. PMID: 17256753.
      View in: PubMed
    108. Wulff H, Kolski-Andreaco A, Sankaranarayanan A, Sabatier JM, Shakkottai V. Modulators of small- and intermediate-conductance calcium-activated potassium channels and their therapeutic indications. Curr Med Chem. 2007; 14(13):1437-57. PMID: 17584055.
      View in: PubMed
    109. Beeton C, Wulff H, Standifer NE, Azam P, Mullen KM, Pennington MW, Kolski-Andreaco A, Wei E, Grino A, Counts DR, Wang PH, LeeHealey CJ, S Andrews B, Sankaranarayanan A, Homerick D, Roeck WW, Tehranzadeh J, Stanhope KL, Zimin P, Havel PJ, Griffey S, Knaus HG, Nepom GT, Gutman GA, Calabresi PA, Chandy KG. Kv1.3 channels are a therapeutic target for T cell-mediated autoimmune diseases. Proc Natl Acad Sci U S A. 2006 Nov 14; 103(46):17414-9. PMID: 17088564; PMCID: PMC1859943.
      View in: PubMed, PubMed Central
    110. Harvey AJ, Baell JB, Toovey N, Homerick D, Wulff H. A new class of blockers of the voltage-gated potassium channel Kv1.3 via modification of the 4- or 7-position of khellinone. J Med Chem. 2006 Feb 23; 49(4):1433-41. PMID: 16480279.
      View in: PubMed
    111. Wei AD, Gutman GA, Aldrich R, Chandy KG, Grissmer S, Wulff H. International Union of Pharmacology. LII. Nomenclature and molecular relationships of calcium-activated potassium channels. Pharmacol Rev. 2005 Dec; 57(4):463-72. PMID: 16382103.
      View in: PubMed
    112. Mouhat S, Teodorescu G, Homerick D, Visan V, Wulff H, Wu Y, Grissmer S, Darbon H, De Waard M, Sabatier JM. Pharmacological profiling of Orthochirus scrobiculosus toxin 1 analogs with a trimmed N-terminal domain. Mol Pharmacol. 2006 Jan; 69(1):354-62. PMID: 16234482.
      View in: PubMed
    113. Schmitz A, Sankaranarayanan A, Azam P, Schmidt-Lassen K, Homerick D, Hänsel W, Wulff H. Design of PAP-1, a selective small molecule Kv1.3 blocker, for the suppression of effector memory T cells in autoimmune diseases. Mol Pharmacol. 2005 Nov; 68(5):1254-70. PMID: 16099841.
      View in: PubMed
    114. Rus H, Pardo CA, Hu L, Darrah E, Cudrici C, Niculescu T, Niculescu F, Mullen KM, Allie R, Guo L, Wulff H, Beeton C, Judge SI, Kerr DA, Knaus HG, Chandy KG, Calabresi PA. The voltage-gated potassium channel Kv1.3 is highly expressed on inflammatory infiltrates in multiple sclerosis brain. Proc Natl Acad Sci U S A. 2005 Aug 02; 102(31):11094-9. PMID: 16043714; PMCID: PMC1182417.
      View in: PubMed, PubMed Central
    115. Beeton C, Pennington MW, Wulff H, Singh S, Nugent D, Crossley G, Khaytin I, Calabresi PA, Chen CY, Gutman GA, Chandy KG. Targeting effector memory T cells with a selective peptide inhibitor of Kv1.3 channels for therapy of autoimmune diseases. Mol Pharmacol. 2005 Apr; 67(4):1369-81. PMID: 15665253; PMCID: PMC4275123.
      View in: PubMed, PubMed Central
    116. Mouhat S, Visan V, Ananthakrishnan S, Wulff H, Andreotti N, Grissmer S, Darbon H, De Waard M, Sabatier JM. K+ channel types targeted by synthetic OSK1, a toxin from Orthochirus scrobiculosus scorpion venom. Biochem J. 2005 Jan 01; 385(Pt 1):95-104. PMID: 15588251; PMCID: PMC1134677.
      View in: PubMed, PubMed Central
    117. Norton RS, Pennington MW, Wulff H. Potassium channel blockade by the sea anemone toxin ShK for the treatment of multiple sclerosis and other autoimmune diseases. Curr Med Chem. 2004 Dec; 11(23):3041-52. PMID: 15578998.
      View in: PubMed
    118. Wulff H, Knaus HG, Pennington M, Chandy KG. K+ channel expression during B cell differentiation: implications for immunomodulation and autoimmunity. J Immunol. 2004 Jul 15; 173(2):776-86. PMID: 15240664.
      View in: PubMed
    119. Vennekamp J, Wulff H, Beeton C, Calabresi PA, Grissmer S, Hänsel W, Chandy KG. Kv1.3-blocking 5-phenylalkoxypsoralens: a new class of immunomodulators. Mol Pharmacol. 2004 Jun; 65(6):1364-74. PMID: 15155830.
      View in: PubMed
    120. Chandy KG, Wulff H, Beeton C, Pennington M, Gutman GA, Cahalan MD. K+ channels as targets for specific immunomodulation. Trends Pharmacol Sci. 2004 May; 25(5):280-9. PMID: 15120495; PMCID: PMC2749963.
      View in: PubMed, PubMed Central
    121. Baell JB, Gable RW, Harvey AJ, Toovey N, Herzog T, Hänsel W, Wulff H. Khellinone derivatives as blockers of the voltage-gated potassium channel Kv1.3: synthesis and immunosuppressive activity. J Med Chem. 2004 Apr 22; 47(9):2326-36. PMID: 15084131.
      View in: PubMed
    122. Mouhat S, Mosbah A, Visan V, Wulff H, Delepierre M, Darbon H, Grissmer S, De Waard M, Sabatier JM. The 'functional' dyad of scorpion toxin Pi1 is not itself a prerequisite for toxin binding to the voltage-gated Kv1.2 potassium channels. Biochem J. 2004 Jan 01; 377(Pt 1):25-36. PMID: 12962541; PMCID: PMC1223833.
      View in: PubMed, PubMed Central
    123. Gutman GA, Chandy KG, Adelman JP, Aiyar J, Bayliss DA, Clapham DE, Covarriubias M, Desir GV, Furuichi K, Ganetzky B, Garcia ML, Grissmer S, Jan LY, Karschin A, Kim D, Kuperschmidt S, Kurachi Y, Lazdunski M, Lesage F, Lester HA, McKinnon D, Nichols CG, O'Kelly I, Robbins J, Robertson GA, Rudy B, Sanguinetti M, Seino S, Stuehmer W, Tamkun MM, Vandenberg CA, Wei A, Wulff H, Wymore RS. International Union of Pharmacology. XLI. Compendium of voltage-gated ion channels: potassium channels. Pharmacol Rev. 2003 Dec; 55(4):583-6. PMID: 14657415.
      View in: PubMed
    124. Wulff H, Beeton C, Chandy KG. Potassium channels as therapeutic targets for autoimmune disorders. Curr Opin Drug Discov Devel. 2003 Sep; 6(5):640-7. PMID: 14579513.
      View in: PubMed
    125. Köhler R, Wulff H, Eichler I, Kneifel M, Neumann D, Knorr A, Grgic I, Kämpfe D, Si H, Wibawa J, Real R, Borner K, Brakemeier S, Orzechowski HD, Reusch HP, Paul M, Chandy KG, Hoyer J. Blockade of the intermediate-conductance calcium-activated potassium channel as a new therapeutic strategy for restenosis. Circulation. 2003 Sep 02; 108(9):1119-25. PMID: 12939222.
      View in: PubMed
    126. Wulff H, Calabresi PA, Allie R, Yun S, Pennington M, Beeton C, Chandy KG. The voltage-gated Kv1.3 K(+) channel in effector memory T cells as new target for MS. J Clin Invest. 2003 Jun; 111(11):1703-13. PMID: 12782673; PMCID: PMC156104.
      View in: PubMed, PubMed Central
    127. Beeton C, Wulff H, Singh S, Botsko S, Crossley G, Gutman GA, Cahalan MD, Pennington M, Chandy KG. A novel fluorescent toxin to detect and investigate Kv1.3 channel up-regulation in chronically activated T lymphocytes. J Biol Chem. 2003 Mar 14; 278(11):9928-37. PMID: 12511563.
      View in: PubMed
    128. Bardien-Kruger S, Wulff H, Arieff Z, Brink P, Chandy KG, Corfield V. Characterisation of the human voltage-gated potassium channel gene, KCNA7, a candidate gene for inherited cardiac disorders, and its exclusion as cause of progressive familial heart block I (PFHBI). Eur J Hum Genet. 2002 Jan; 10(1):36-43. PMID: 11896454.
      View in: PubMed
    129. Ayabe T, Wulff H, Darmoul D, Cahalan MD, Chandy KG, Ouellette AJ. Modulation of mouse Paneth cell alpha-defensin secretion by mIKCa1, a Ca2+-activated, intermediate conductance potassium channel. J Biol Chem. 2002 Feb 01; 277(5):3793-800. PMID: 11724775.
      View in: PubMed
    Heike's Networks
    Concepts
    Derived automatically from this person's publications.
    See all (567) concept(s)
    _
    Co-Authors
    People in Profiles who have published with this person.
    See all (32) people
    _
    Related Authors
    People who share related concepts with this person.
    See all (60) people
    _
    ↑